Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
Crossref DOI link: https://doi.org/10.1136/bcr-2020-236934
Published Online: 2020-12-22
Published Print: 2020-12
Update policy: https://doi.org/10.1136/crossmarkpolicy
Barbaro, Daniele http://orcid.org/0000-0002-1474-7178
Lapi, Paola
Viacava, Paolo
Torregrossa, Liborio
License valid from 2020-12-22